0
Signin
countryflagUS

18889881171

AAPL 186.28 1.7645% MSFT 413.72 -0.2459% GOOG 170.9 0.3582% GOOGL 169.14 0.2905% AMZN 186.57 -0.4854% NVDA 903.99 0.5797% META 468.01 -1.7199% TSLA 171.89 2.03% TSM 146.41 -1.9094% LLY 757.7 -0.3026% V 279.39 -0.4809% AVGO 1337.51 0.3534% JPM 198.73 -0.0201% UNH 511.74 -0.2087% NVO 132.41 3.107% WMT 60.41 -0.1157% LVMUY 168.75 -0.4601% XOM 117.88 -0.0678% LVMHF 844.4 -0.6588% MA 457.76 0.1707%

Acura Pharmaceuticals Inc

Healthcare US ACUR

0.0041USD
-(-%)

Last update at 2024-05-10T13:30:00Z

Day Range

0.00410.0041
LowHigh

52 Week Range

0.00020.05
LowHigh

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2021-12-31 2020-12-31 2019-12-31 2018-12-31 2017-12-31
Type yearly yearly yearly yearly yearly
Date 2021-12-31 2020-12-31 2019-12-31 2018-12-31 2017-12-31
Income before tax -0.87900M -1.20800M -3.77400M -3.84200M -5.81700M
Minority interest - - - - -
Net income -0.87900M -1.20800M -3.77400M -3.84200M -5.68200M
Selling general administrative 1.25M 2.55M 1.88M 2.57M 4.34M
Selling and marketing expenses - - - - -
Gross profit - 3.57M 2.66M 0.41M 2.84M
Reconciled depreciation 0.09M 0.12M 0.27M 0.28M 0.29M
Ebit - -0.75800M -3.32500M -3.61900M -5.22100M
Ebitda -0.67900M -0.63300M -3.03900M -3.16700M -4.92700M
Depreciation and amortization - - - - -
Non operating income net other - - -2.60000M 0.30M 0.00400M
Operating income -1.21400M -0.75800M -0.72500M -3.91500M -5.22500M
Other operating expenses - - - - -
Interest expense 0.20M 0.45M 0.46M 0.40M 0.00000M
Tax provision 0.00000M 0.00000M 0.00000M 0.00000M -0.13500M
Interest income - 0.00000M 0.01M 0.17M 0.00400M
Net interest income -0.20000M -0.45000M -0.44900M -0.22300M -0.59200M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - - - - -0.13500M
Total revenue 1.56M 3.57M 2.66M 0.41M 2.97M
Total operating expenses 2.78M 4.33M -3.38200M 4.33M 8.06M
Cost of revenue - - - 0.00000M 0.13M
Total other income expense net 0.54M - -2.60000M 0.30M -0.59200M
Discontinued operations - - - - -
Net income from continuing ops -0.87900M -1.20800M -3.77400M -3.84200M -5.68200M
Net income applicable to common shares - -1.20800M -3.77400M -3.84200M -5.68200M
Preferred stock and other adjustments - - - - -
Breakdown 2021-12-31 2020-12-31 2019-12-31 2018-12-31 2017-12-31
Type yearly yearly yearly yearly yearly
Date 2021-12-31 2020-12-31 2019-12-31 2018-12-31 2017-12-31
Total assets 0.86M 1.74M 2.56M 2.15M 4.60M
Intangible assets - 0.07M 0.81M 1.02M 1.22M
Earning assets - - - - -
Other current assets 0.15M 1.18M 1.14M 0.39M 0.35M
Total liab 0.68M 7.63M 7.30M 5.77M 4.63M
Total stockholder equity 0.18M -5.89100M -4.74100M -3.61700M -0.02700M
Deferred long term liab - - - - -
Other current liab 0.52M 0.70M 0.25M 0.23M 0.29M
Common stock - 0.22M 0.21M 0.21M 0.21M
Capital stock 0.65M 0.22M 0.21M 0.21M -
Retained earnings -390.08300M -389.20400M -387.99600M -384.22200M -380.38000M
Other liab - - 0.23M 0.11M -
Good will - - - - -
Other assets - - 0.03M 0.07M 0.14M
Cash 0.07M 0.41M 0.86M 0.09M 2.22M
Cash and equivalents - - - - -
Total current liabilities 0.52M 7.52M 1.07M 1.44M 4.63M
Current deferred revenue - - - - -
Net debt 0.15M 5.86M 5.14M 4.13M 0.47M
Short term debt - 6.16M - - 2.69M
Short long term debt - 6.16M - - 2.69M
Short long term debt total - - - - -
Other stockholder equity - - - - -
Property plant equipment - 0.48M 0.54M 0.61M 0.68M
Total current assets 0.37M 1.18M 1.18M 0.46M 2.57M
Long term investments - - 0.03M 0.07M 0.14M
Net tangible assets - -5.96400M -5.55100M -4.63400M -1.25100M
Short term investments - - - - -
Net receivables 0.16M 0.63M 0.03M 0.07M 0.07M
Long term debt 0.15M 0.10M 6.00M 4.22M -
Inventory - - - - 0.00000M
Accounts payable 0.19M 0.66M 0.82M 1.20M 1.64M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -
Additional paid in capital - - - - -
Common stock total equity - 0.22M 0.21M 0.21M 0.21M
Preferred stock total equity - - - - -
Retained earnings total equity - -389.20400M -387.99600M -384.22200M -380.38000M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.05M - 0.84M 1.08M 1.36M
Deferred long term asset charges - - - - -
Non current assets total 0.49M 0.56M 1.38M 1.69M 2.04M
Capital lease obligations 0.05M - - - -
Long term debt total - - 6.00M - -
Breakdown 2021-12-31 2020-12-31 2019-12-31 2018-12-31 2017-12-31
Type yearly yearly yearly yearly yearly
Date 2021-12-31 2020-12-31 2019-12-31 2018-12-31 2017-12-31
Investments - - - 0.00000M 0.31M
Change to liabilities - -0.37300M -0.36100M -0.33600M 0.23M
Total cashflows from investing activities - - - - 0.31M
Net borrowings - 0.27M 1.38M 1.78M -2.76000M
Total cash from financing activities 0.39M 0.27M 1.39M 1.78M 1.24M
Change to operating activities - 0.49M 0.45M -0.71900M 0.29M
Net income -0.87900M -1.20800M -3.77400M -3.84200M -5.68200M
Change in cash -0.34800M -0.44900M 0.77M -2.12900M -2.96100M
Begin period cash flow 0.41M 0.86M 0.09M 2.22M 5.18M
End period cash flow 0.07M 0.41M 0.86M 0.09M 2.22M
Total cash from operating activities -0.74200M -0.71900M -0.61800M -3.90800M -4.51000M
Issuance of capital stock 0.00300M 0.00300M 0.01M 0.00200M -
Depreciation 0.09M 0.12M 0.34M 0.37M 0.39M
Other cashflows from investing activities - - - - 0.31M
Dividends paid - - - - -
Change to inventory - - - 0.00000M 0.10M
Change to account receivables - -0.46700M -0.02300M -0.06600M 0.02M
Sale purchase of stock - - - - 4.00M
Other cashflows from financing activities - 0.00100M 0.01M 0.00200M -
Change to netincome - 0.70M 2.71M -0.07800M 0.46M
Capital expenditures 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Change receivables - - - - 0.02M
Cash flows other operating - 0.03M 0.47M -0.01900M -0.03500M
Exchange rate changes - - - - -
Cash and cash equivalents changes - -0.44900M 0.77M -2.12900M -2.96100M
Change in working capital 0.48M -0.34000M 0.12M -0.18300M 0.27M
Stock based compensation 0.06M 0.04M 0.11M - -
Other non cash items - -0.22300M 0.05M -0.08500M 0.10M
Free cash flow -0.74200M -0.71900M -0.61800M -3.90800M -4.51000M

Fundamentals

  • Previous Close 0.0041
  • Market Cap0.00007M
  • Volume0
  • P/E Ratio-
  • Dividend Yield2.94%
  • EBITDA-1.14100M
  • Revenue TTM1.56M
  • Revenue Per Share TTM0.03
  • Gross Profit TTM 0.04M
  • Diluted EPS TTM-0.02

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ACUR
Acura Pharmaceuticals Inc		 - -% 0.0041 - - - 0.22 0.11 -0.2964
ZTS
Zoetis Inc		 -1.13 0.67% 167.91 40.18 30.96 10.67 17.60 11.27 26.18
MKKGY
Merck KGaA ADR		 -0.14 0.42% 33.32 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 -4.045 2.40% 164.31 21.73 14.95 3.16 2.15 3.56 12.82
TAK
Takeda Pharmaceutical Co Ltd ADR		 -0.14 1.06% 13.11 32.67 11.53 0.01 0.87 0.02 0.07

Reports Covered

Stock Research & News

View All

Profile

Acura Pharmaceuticals, Inc., an innovative drug delivery company, engages in the research, development, and commercialization of technologies and products to address safe use of medications in the United States. It offers Oxaydo tablets, a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain; and Nexafed products, which are pseudoephedrine and acetaminophen tablets that are used as nasal decongestants in various non-prescription and prescription cold, sinus, and allergy products. Acura Pharmaceuticals, Inc. has collaboration and license agreements with Egalet US, Inc. and Egalet Ltd. to manufacture and commercialize Oxaydo products worldwide; and development and commercialization agreement with Abuse Deterrent Pharma, LLC to develop LTX-03, an immediate-release tablets utilizing LIMITx technology. The company was formerly known as Halsey Drug Co., Inc. The company was incorporated in 1935 and is based in Palatine, Illinois. Acura Pharmaceuticals, Inc. is a subsidiary of Abuse Deterrent Pharma, LLC.

Acura Pharmaceuticals Inc

616 N. North Court, Palatine, IL, United States, 60067

Key Executives

Name Title Year Born
Mr. Robert B. Jones CEO, Pres & Director 1959
Mr. Peter A. Clemens Sr. VP, CFO & Sec. 1953
Dr. Albert W. Brzeczko Ph.D. VP of Pharmaceutical Sciences of Acura Pharmaceutical Technologies, Inc. 1957
Mr. Robert A. Seiser CPA, Ph.D. VP, Treasurer & Corp. Controller 1964

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).